Read the full stored bill text
Florida Senate
-
2026
SB 1060
By
Senator Rodriguez
40-00931A-26 20261060__
1 A bill to be entitled
2 An act relating to the neurofibromatosis research
3 grants; creating s. 381.994, F.S.; creating the
4 Neurofibromatosis Disease Grant Program within the
5 Department of Health; providing the purpose of the
6 program; providing that, subject to legislative
7 appropriation, the program award grants for certain
8 purposes; specifying entities that are eligible to
9 apply for grants under the program; allowing certain
10 grant proposals to receive preference in the awarding
11 of grants; requiring the department to award grants
12 after consulting with the Rare Disease Advisory
13 Council; specifying the types of applications that may
14 be considered for grant funding; requiring the
15 department to appoint peer review panels to review the
16 scientific merit of grant applications and establish
17 their priority scores; requiring the council to
18 consider the priority scores in determining which
19 proposals are recommended for grant funding under the
20 program; requiring the council and peer review panels
21 to establish and follow certain guidelines when
22 performing their duties under the program; prohibiting
23 members of the council or peer review panels from
24 participating in discussions or decisions if there are
25 certain conflicts of interest; authorizing certain
26 appropriated funds to be carried forward under certain
27 circumstances; providing an effective date.
28
29 Be It Enacted by the Legislature of the State of Florida:
30
31 Section 1. Section 381.994, Florida Statutes, is created to
32 read:
33
381.994
Neurofibromatosis Disease Grant Program.—
34
(1)(a)
There is created within the Department of Health the
35
Neurofibromatosis Disease Grant Program. The purpose of the
36
program is to advance the progress of research and cures for
37
neurofibromatosis by awarding grants through a competitive,
38
peer-reviewed process.
39
(b)
Subject to an annual recurring appropriation of $5
40
million by the Legislature, the program shall award grants for
41
scientific and clinical research to further the search for new
42
diagnostics, treatments, and cures for neurofibromatosis.
43
(2)(a) Applications for grants for neurofibromatosis
44
disease research may be submitted by any university or
45
established research institute in th
is
state. All qualified
46
investigators in this state, regardless of institutional
47
affiliation, shall have equal access and opportunity to compete
48
for the research funding. Preference may be given to grant
49
proposals that foster collaboration among institutions,
50
researchers, and community practitioners, as such proposals
51
support the advancement of treatments and cures of
52
neurofibromatosis through basic or applied research. Grants
53
shall be awarded by the department, after consultation with the
54
Rare Disease Advisory Council
under
s. 381.99, on the basis of
55
scientific merit, as determined by the competitive, peer
56
reviewed process to ensure objectivity, consistency, and high
57
quality. The following types of applications may be considered
58
for funding:
59
1. Investigator-initiated research grants.
60
2. Institutional research grants.
61
3. Collaborative research grants, including those that
62
advance the finding of treatment and cures through basic or
63
applied research.
64
(b) To ensure appropriate and fair evaluation of grant
65
applications based on scientific merit, the department shall
66
appoint peer review panels of independent, scientifically
67
qualified individuals to review the scientific merit of each
68
proposal and establish its priority score. The priority scores
69
shall be forwarded to the council and must be considered in
70
determining which proposals are recommended for funding.
71
(3) For purposes of performing their duties under this
72
section, the Rare Disease Advisory Council and the peer review
73
panels shall establish and follow rigorous guidelines for
74
ethical conduct and adhere to a strict policy with regard to
75
conflicts of interest. A member of the council or panel may not
76
participate in any discussion or decision of the council or
77
panel with respect to a research proposal by any firm, entity,
78
or agency with which the member is associated as a member of the
79
governing body or as an employee or with which the member has
80
entered into a contractual arrangement.
81
(4) Notwithstanding s. 216.301 and pursuant to s. 216.351,
82
the balance of any appropriation from the General Revenue Fund
83
for the Neurofibromatosis Disease Grant Program which is not
84
disbursed but is obligated pursuant to contract or committed to
85
be expended by June 30 of the fiscal year in which the funds are
86
appropriated may be carried forward for up to 5 years after the
87
effective date of the original appropriation.
88 Section 2. This act shall take effect July 1, 2026.